EUVIMEDEUVIMED entdecken
Crossref

Neoadjuvant chemoradiotherapy using moderately hypofractionated intensity-modulated radiotherapy for borderline resectable pancreatic cancer

Takahiro Iwai iD, Michio Yoshimura, Yuka Ono, Ayaka Ogawa, Ryo Ashida, Toshihiko Masui, Kazuyuki Nagai, Takayuki Anazawa, Yousuke Kasai, Kei Yamane, Etsuro Hatano, Masashi Kanai und 3 weitere

Strahlentherapie und Onkologie · 2025

DOI: 10.1007/s00066-025-02433-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Strahlentherapie und Onkologie, 2025. Verfasst von Takahiro Iwai und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology and Image-Applied Therapy, Graduate School of Medicine, Kyoto University, Kyoto, Japan. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Neoadjuvant Therapy, Radiotherapy, Intensity-Modulated, Radiation Dose Hypofractionation. Die Arbeit nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To evaluate the outcome and prognostic factors for borderline resectable pancreatic cancer (BRPC) patients treated with neoadjuvant chemoradiotherapy using moderately hypofractionated intensity-modulated radiotherapy (NAC-MH-IMRT). METHODS: Patients with BRPC treated with NAC-MH-IMRT at 42 Gy in 15 fractions between February 2013 and June 2021 were evaluated. The overall survival (OS), progression-free survival (PFS), cumulative incidence of locoregional failure and distant metastases, association dose-volume indices, Evans grade for pathological response, and toxicities were evaluated. RESULTS: A total of 66 patients met the inclusion criteria, and the median follow-up period was 23.9 months. In all, 48 patients underwent pancreatectomy, and margin-negative resection was achieved in 44 patients (91.7%). The median survival and PFS times were 34.8 months and 12.0 months, respectively, for the whole cohort. The 2‑year cumulative incidences of locoregional recurrence and distant metastases in the resected group were 25.7 and 52.8%, respectively. From the Mann-Whitney U test, the minimum dose of the primary gross tumor volume (GTVmin) of the group with Evans grade ≥ 2b was statistically higher than that of the other group (38.6 Gy vs. 37.3 Gy, p = 0.005). However, this was not associated with reduced cumulative incidence of locoregional failure. No patient had grade ≥ 3 acute gastrointestinal toxicity. CONCLUSION: NAC-MH-IMRT for BRPC resulted in good survival outcomes and margin-negative resection rates. High GTVmin was associated with good pathological response; however, improvement of local control requires further investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsNeoadjuvant TherapyRadiotherapy, Intensity-ModulatedRadiation Dose HypofractionationChemoradiotherapy, AdjuvantHumansMaleFemaleMiddle AgedAgedPrognosisPancreatectomyAdultTreatment OutcomeNeoplasm Recurrence, LocalRetrospective StudiesAged, 80 and overFollow-Up Studies

Stichwörter der Autor:innen

Borderline resectable pancreatic cancerModerately hypofractionated radiotherapyNeoadjuvant therapyPathological responsePrognostic radiotherapeutic factorsTreatment outcomes

Autor:innen und Institutionen

  • Department of Radiation Oncology and Image-Applied Therapy, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Department of Radiation Oncology and Image-Applied Therapy, Graduate School of Medicine, Kyoto University, Kyoto, Japan. myossy@kuhp.kyoto-u.ac.jp.
  • Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Department of Surgery, Kurashiki Central Hospital, Okayama, Japan.
  • Department of Clinical Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Department of Gastroenterology and Hepatology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

ORCID-Profile: Takahiro Iwai

Zitieren

APA

Iwai, T., Yoshimura, M., Ono, Y., Ogawa, A., Ashida, R., Masui, T., Nagai, K., Anazawa, T., Kasai, Y., Yamane, K., Hatano, E., Kanai, M., Fukuda, A., Isoda, H., & Mizowaki, T. (2025). Neoadjuvant chemoradiotherapy using moderately hypofractionated intensity-modulated radiotherapy for borderline resectable pancreatic cancer. Strahlentherapie und Onkologie. https://doi.org/10.1007/s00066-025-02433-9

Vancouver

Iwai T, Yoshimura M, Ono Y, Ogawa A, Ashida R, Masui T, et al. Neoadjuvant chemoradiotherapy using moderately hypofractionated intensity-modulated radiotherapy for borderline resectable pancreatic cancer. Strahlentherapie und Onkologie. 2025. doi:10.1007/s00066-025-02433-9

BibTeX
@article{Iwai2025,
  author = {Iwai, Takahiro and Yoshimura, Michio and Ono, Yuka and Ogawa, Ayaka and Ashida, Ryo and Masui, Toshihiko and Nagai, Kazuyuki and Anazawa, Takayuki and Kasai, Yousuke and Yamane, Kei and Hatano, Etsuro and Kanai, Masashi and Fukuda, Akihisa and Isoda, Hiroyoshi and Mizowaki, Takashi},
  title = {Neoadjuvant chemoradiotherapy using moderately hypofractionated intensity-modulated radiotherapy for borderline resectable pancreatic cancer},
  journal = {Strahlentherapie und Onkologie},
  year = {2025},
  doi = {10.1007/s00066-025-02433-9}
}
Kostenlos starten →